GET DAILY SIGNALSSupernus Pharmaceuticals (SUPN) Posts +18% Revenue Growth in Q3 2026
Key Takeaways
- Supernus reported record third-quarter 2026 total revenue of $226.8 million, up 18% year over year and above consensus estimates of roughly $218 million.
- GAAP net income reached $20.9 million, or $0.35 per diluted share, versus a net loss of $45.1 million, or a loss of $0.80 per share, in the prior-year quarter.
- Adjusted (non-GAAP) operating earnings rose to $55.2 million from $41.9 million a year earlier.
- Combined revenue from the four growth products — Qelbree, GOCOVRI, ZURZUVAE, and ONAPGO — climbed 43% year over year.
- Management raised full-year 2026 revenue guidance to $875 million–$900 million and adjusted operating earnings guidance to $160 million–$180 million.
- The all-stock merger with Indivior Pharmaceuticals was approved by both companies' shareholders and is expected to close on November 2, 2026.
Earnings Context and Why It Matters
This quarterly earnings release arrives at a pivotal moment for Supernus Pharmaceuticals, a Rockville, Maryland-based biopharmaceutical company focused on central nervous system (CNS) diseases. The report lands just days before the company's planned all-stock combination with Indivior Pharmaceuticals, a merger that would create a diversified CNS leader spanning psychiatry, neurology, and addiction. Investors are watching whether Supernus can sustain the momentum of its growth portfolio — particularly Qelbree, ZURZUVAE, GOCOVRI, and ONAPGO — while demonstrating improved operating efficiency. The results also matter because they reflect the final standalone quarter before the combined entity begins trading, offering a baseline for assessing the merger's integration and cost-synergy story. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Reported Results
Supernus delivered record total revenue of $226.8 million for the third quarter ended September 30, 2026, an 18% increase from $192.1 million in the same period last year. The figure topped Wall Street consensus estimates, which clustered near $218 million. Net product sales totaled $178.6 million, while collaboration revenue tied to ZURZUVAE reached $41.7 million and royalty, licensing, and other revenue contributed $6.5 million.
On the bottom line, GAAP net earnings were $20.9 million, or $0.35 per diluted share, a sharp turnaround from a GAAP net loss of $45.1 million, or a loss of $0.80 per diluted share, a year earlier. GAAP operating earnings came in at $21.2 million versus an operating loss of $60.2 million in the prior-year quarter. Adjusted (non-GAAP) operating earnings rose to $55.2 million from $41.9 million, reflecting the absence of acquisition-related costs tied to the 2025 Sage Therapeutics transaction.
Growth-product momentum was a clear highlight. Qelbree generated $90.8 million in net sales, GOCOVRI reached a record $42.6 million, ONAPGO grew to $17.1 million, and ZURZUVAE collaboration revenue more than doubled. Management also raised standalone 2026 guidance, lifting total revenue to $875 million–$900 million and adjusted operating earnings to $160 million–$180 million.
Market Reaction and Investor Sentiment
Despite revenue and earnings that beat the prior year and exceeded revenue consensus, the stock's immediate reaction was muted. Shares slipped roughly 2% in early post-report trading, suggesting that some investors had already priced in the strong growth-product trajectory and were looking ahead to the merger close. The conflicting analyst EPS expectations also muddy the picture: some consensus figures anticipated a small loss, while others modeled a higher profit, making the headline EPS comparison less straightforward.
Investor sentiment remains focused less on the standalone quarter and more on execution of the Indivior combination. With shareholder approval secured on October 15 and a November 2 closing expected, attention is shifting to integration risk, the realization of the $125 million in anticipated annual cost synergies, and how the combined 11-product portfolio performs in 2027.
Forward Outlook and Key Factors to Monitor
Looking ahead, the most important catalyst is the closing of the Indivior merger on November 2, 2026. Once complete, the standalone guidance issued this quarter will no longer apply, and the market will focus on the combined company's revised financial framework and integration timeline. Management expects to provide combined full-year guidance shortly after closing.
Investors should watch whether the growth portfolio sustains its momentum into 2027. Qelbree's prescriptions grew 18% year over year in the quarter, outpacing the broader ADHD (attention-deficit hyperactivity disorder) market, while ZURZUVAE's U.S. sales, as reported by Biogen, rose approximately 53%. ONAPGO also gained a favorable regulatory tailwind after the FDA recognized seven years of orphan drug exclusivity.
Additional factors to monitor include progress on pipeline programs such as SPN-820 and SPN-817, which continue enrolling in Phase IIb studies, and the SPN-443 program, expected to begin a Phase I study by the end of 2026. Cost discipline, margin trends, and the pace of merger cost-synergy capture will also shape how investors assess the newly combined entity in the quarters ahead. From what I see, these pipeline updates could provide important visibility once the merger closes.
Exploring AI Tools for Deeper Analysis
In my own research process, I often turn to Tickeron’s AI Screener to quickly filter pharmaceutical names and compare technical and fundamental signals across the sector. It helps surface relevant peers and trend data without spending hours on manual screening, which keeps the focus on the key drivers like revenue growth and merger integration for names such as SUPN.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
SUPN's RSI Oscillator ascends from oversold territory
The RSI Indicator for SUPN moved out of oversold territory on October 19, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 26 similar instances when the indicator left oversold territory. In 21 of the 26 cases the stock moved higher. This puts the odds of a move higher at 81%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 47 of 61 cases where SUPN's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 77%.
The Momentum Indicator moved above the 0 level on October 28, 2026. You may want to consider a long position or call options on SUPN as a result. In 75 of 97 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 77%.
The Moving Average Convergence Divergence (MACD) for SUPN just turned positive on October 22, 2026. Looking at past instances where SUPN's MACD turned positive, the stock continued to rise in 39 of 51 cases over the following month. The odds of a continued upward trend are 76%.
Following a +0.76% 3-day Advance, the price is estimated to grow further. Considering data from situations where SUPN advanced for three days, in 225 of 313 cases, the price rose further within the following month. The odds of a continued upward trend are 72%.
SUPN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SUPN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 64%.
The Aroon Indicator for SUPN entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 27 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.362) is normal, around the industry mean (8.801). P/E Ratio (-21.792) is within average values for comparable stocks, (-2.500). Projected Growth (PEG Ratio) (0.900) is also within normal values, averaging (2.152). Dividend Yield (0.000) settles around the average of (0.044) among similar stocks. P/S Ratio (2.863) is also within normal values, averaging (178.797).
The Tickeron Profit vs. Risk Rating rating for this company is 56 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock slightly better than average.
The Tickeron Price Growth Rating for this company is 72 (best 1 - 100 worst), indicating slightly worse than average price growth. SUPN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer for the treatment of central nervous system
Industry PharmaceuticalsGeneric
Advertisement